Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001654954-17-010141
Filing Date
2017-11-07
Accepted
2017-11-07 16:15:11
Documents
54
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT mbvx10q_sep302017.htm 10-Q 958437
2 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF ex31-1.htm EX-31.1 12760
3 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF ex31-2.htm EX-31.2 12989
4 CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE ex32.htm EX-32 10466
  Complete submission text file 0001654954-17-010141.txt   3244135

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT mbvx-20170930.xml EX-101.INS 444321
6 XBRL TAXONOMY EXTENSION SCHEMA mbvx-20170930.xsd EX-101.SCH 31955
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE mbvx-20170930_cal.xml EX-101.CAL 50893
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbvx-20170930_def.xml EX-101.DEF 91455
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbvx-20170930_lab.xml EX-101.LAB 239923
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbvx-20170930_pre.xml EX-101.PRE 190336
Mailing Address 11535 SORRENTO VALLEY ROAD SUITE 400 SAN DIEGO CA 92121
Business Address 11535 SORRENTO VALLEY ROAD SUITE 400 SAN DIEGO CA 92121 8582599405
MABVAX THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001109196 (see all company filings)

EIN.: 930987903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37861 | Film No.: 171183532
SIC: 2834 Pharmaceutical Preparations